Pyrogallol acts as a novel anticancer factor to enhance the sensitivity to cisplatin in ovarian cancer cells through inducing miR-15a upregulation

Abstract Introduction Pyrogallol is a catechin compound, as an active ingredient extracted from Emblica officinalis, has antiproliferative and antiapoptotic effects on some of the human cancer cells. Cisplatin is known as an effective chemotherapeutic agent against cancer by inducing DNA damage and...

Full description

Saved in:
Bibliographic Details
Main Authors: Azin Shirani, Razieh Mirabbasi, Leila Shabani, Somayeh Reiisi
Format: Article
Language:English
Published: SpringerOpen 2025-01-01
Series:Egyptian Journal of Medical Human Genetics
Subjects:
Online Access:https://doi.org/10.1186/s43042-025-00647-1
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832585646115389440
author Azin Shirani
Razieh Mirabbasi
Leila Shabani
Somayeh Reiisi
author_facet Azin Shirani
Razieh Mirabbasi
Leila Shabani
Somayeh Reiisi
author_sort Azin Shirani
collection DOAJ
description Abstract Introduction Pyrogallol is a catechin compound, as an active ingredient extracted from Emblica officinalis, has antiproliferative and antiapoptotic effects on some of the human cancer cells. Cisplatin is known as an effective chemotherapeutic agent against cancer by inducing DNA damage and apoptosis. However, the effect of pyrogallol alone and in combination with cisplatin on proliferation and apoptosis of ovarian cancer has not yet been reported. Methods In the present study, ovarian carcinoma cell line A2780 was cultivated, and the anticancer properties of pyrogallol and cisplatin determined by cell treatment of the two drugs separately and combination. Cell viability and apoptosis rate was investigated by MTT assay and flow cytometry. The effects of the compounds in inhibiting colony formation and migration were measured by colony formation and scratch methods. Results The results of the present study revealed that pyrogallol significantly inhibited the proliferation of A2780 cells in a dose-dependent manner. The combination treatment of pyrogallol and cisplatin exhibited a prominent inhibitory effect on the growth, colony formation and migration, and increased the induction of apoptosis up to 2.5 times compared to single treatments. Also, the qPCR results showed a significant increase in the expression of miR-15a and a decrease in the expression of miRNA target genes under treatment with the drugs both separately and in their combination. Conclusion This study suggests that the combination treatment of pyrogallol and cisplatin significantly increases the death of ovarian cancer cells by inducing apoptosis. Therefore, it can boost the efficacy of chemotherapy and reduce its side effects. It is hoped that the findings of the present study can provide a new perspective for pyrogallol as a therapeutic agent in the treatment of ovarian cancer.
format Article
id doaj-art-7f846e5b378d4de6a39a948a522ef61d
institution Kabale University
issn 2090-2441
language English
publishDate 2025-01-01
publisher SpringerOpen
record_format Article
series Egyptian Journal of Medical Human Genetics
spelling doaj-art-7f846e5b378d4de6a39a948a522ef61d2025-01-26T12:36:47ZengSpringerOpenEgyptian Journal of Medical Human Genetics2090-24412025-01-0126111310.1186/s43042-025-00647-1Pyrogallol acts as a novel anticancer factor to enhance the sensitivity to cisplatin in ovarian cancer cells through inducing miR-15a upregulationAzin Shirani0Razieh Mirabbasi1Leila Shabani2Somayeh Reiisi3Department of Genetics, Faculty of Basic Sciences, Shahrekord UniversityDepartment of Biology, Faculty of Science, Shahid Chamran University of AhvazDepartment of Plant Science, Faculty of Science, Shahrekord UniversityDepartment of Genetics, Faculty of Basic Sciences, Shahrekord UniversityAbstract Introduction Pyrogallol is a catechin compound, as an active ingredient extracted from Emblica officinalis, has antiproliferative and antiapoptotic effects on some of the human cancer cells. Cisplatin is known as an effective chemotherapeutic agent against cancer by inducing DNA damage and apoptosis. However, the effect of pyrogallol alone and in combination with cisplatin on proliferation and apoptosis of ovarian cancer has not yet been reported. Methods In the present study, ovarian carcinoma cell line A2780 was cultivated, and the anticancer properties of pyrogallol and cisplatin determined by cell treatment of the two drugs separately and combination. Cell viability and apoptosis rate was investigated by MTT assay and flow cytometry. The effects of the compounds in inhibiting colony formation and migration were measured by colony formation and scratch methods. Results The results of the present study revealed that pyrogallol significantly inhibited the proliferation of A2780 cells in a dose-dependent manner. The combination treatment of pyrogallol and cisplatin exhibited a prominent inhibitory effect on the growth, colony formation and migration, and increased the induction of apoptosis up to 2.5 times compared to single treatments. Also, the qPCR results showed a significant increase in the expression of miR-15a and a decrease in the expression of miRNA target genes under treatment with the drugs both separately and in their combination. Conclusion This study suggests that the combination treatment of pyrogallol and cisplatin significantly increases the death of ovarian cancer cells by inducing apoptosis. Therefore, it can boost the efficacy of chemotherapy and reduce its side effects. It is hoped that the findings of the present study can provide a new perspective for pyrogallol as a therapeutic agent in the treatment of ovarian cancer.https://doi.org/10.1186/s43042-025-00647-1PyrogallolCisplatinOvarian cancerCell proliferationmiR-15a
spellingShingle Azin Shirani
Razieh Mirabbasi
Leila Shabani
Somayeh Reiisi
Pyrogallol acts as a novel anticancer factor to enhance the sensitivity to cisplatin in ovarian cancer cells through inducing miR-15a upregulation
Egyptian Journal of Medical Human Genetics
Pyrogallol
Cisplatin
Ovarian cancer
Cell proliferation
miR-15a
title Pyrogallol acts as a novel anticancer factor to enhance the sensitivity to cisplatin in ovarian cancer cells through inducing miR-15a upregulation
title_full Pyrogallol acts as a novel anticancer factor to enhance the sensitivity to cisplatin in ovarian cancer cells through inducing miR-15a upregulation
title_fullStr Pyrogallol acts as a novel anticancer factor to enhance the sensitivity to cisplatin in ovarian cancer cells through inducing miR-15a upregulation
title_full_unstemmed Pyrogallol acts as a novel anticancer factor to enhance the sensitivity to cisplatin in ovarian cancer cells through inducing miR-15a upregulation
title_short Pyrogallol acts as a novel anticancer factor to enhance the sensitivity to cisplatin in ovarian cancer cells through inducing miR-15a upregulation
title_sort pyrogallol acts as a novel anticancer factor to enhance the sensitivity to cisplatin in ovarian cancer cells through inducing mir 15a upregulation
topic Pyrogallol
Cisplatin
Ovarian cancer
Cell proliferation
miR-15a
url https://doi.org/10.1186/s43042-025-00647-1
work_keys_str_mv AT azinshirani pyrogallolactsasanovelanticancerfactortoenhancethesensitivitytocisplatininovariancancercellsthroughinducingmir15aupregulation
AT raziehmirabbasi pyrogallolactsasanovelanticancerfactortoenhancethesensitivitytocisplatininovariancancercellsthroughinducingmir15aupregulation
AT leilashabani pyrogallolactsasanovelanticancerfactortoenhancethesensitivitytocisplatininovariancancercellsthroughinducingmir15aupregulation
AT somayehreiisi pyrogallolactsasanovelanticancerfactortoenhancethesensitivitytocisplatininovariancancercellsthroughinducingmir15aupregulation